Spravato® (Esketamine) Therapy

Spravato® (Esketamine) Therapy

At Centerpointe Psychiatry, we now offer Spravato® (Esketamine) Therapy, an FDA-approved treatment option for those struggling with treatment-resistant depression (TRD). If you or a loved one has tried traditional antidepressant treatments without experiencing adequate relief, Spravato may offer a new path forward. Administered under medical supervision, Spravato works differently from conventional antidepressants and has helped many patients achieve meaningful improvement in their depressive symptoms.

What is Spravato® (Esketamine)?

Spravato® is an FDA-approved prescription nasal spray containing esketamine, a derivative of ketamine, specifically developed for adults with treatment-resistant depression. Unlike traditional antidepressants, which primarily target serotonin and other neurotransmitters, Spravato works through the brain’s glutamate system—a different pathway involved in mood regulation, learning, and neural connectivity.

Because of its unique mechanism of action, Spravato may help individuals who have not found sufficient relief through conventional treatment approaches. Treatment is administered in a certified healthcare setting under the supervision of trained medical professionals, with monitoring throughout each session to ensure patient safety and comfort.

Spravato may be appropriate for adults who:

• Have been diagnosed with major depressive disorder (MDD)
• Have not experienced adequate improvement after trying multiple antidepressant medications
• Continue to struggle with persistent depressive symptoms that impact daily life and functioning
• Are seeking additional evidence-based treatment options under psychiatric care

A comprehensive psychiatric evaluation is required to determine whether Spravato is an appropriate treatment option for your individual needs.